Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the experimental drug, SG2000 is safe and
tolerable in the treatment of participants with advanced chronic lymphocytic leukemia and
acute myeloid leukemia whose standard treatment did not work, whose cancer came back or who
are not candidates for other types of standard therapy.